Therapeutic Class: Dual GIP and GLP-1 Receptor Agonist
Dosage Form: Prefilled Syringe for Subcutaneous Injection
Strengths Available: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Tirza is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
Not studied in individuals with a history of pancreatitis.
Not approved for type 1 diabetes mellitus.
⚠️ Always take under the supervision of a registered physician.
Tirzepatide is a synthetic 39-amino-acid peptide with a C20 fatty diacid moiety, enhancing its albumin binding and extending its half-life.
It selectively activates GIP and GLP-1 receptors, boosting insulin secretion (first and second phase) and reducing glucagon—both in a glucose-dependent manner.
Route: Subcutaneous injection
Start with 2.5 mg once weekly (initiation dose, not for glycemic control)
After 4 weeks, increase to 5 mg once weekly
Further titration: Increase in 2.5 mg increments every 4 weeks as needed
Maximum dose: 15 mg once weekly
Pediatrics (<18 years): Safety and efficacy not established.
Geriatric patients: No dosage adjustment based solely on age.
Renal or hepatic impairment: Monitor closely; consider dose adjustments based on tolerability.
Missed Dose: